At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $43.37, up 4.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IONS shares have gain 2.34% over the last week, with a monthly amount glided 9.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on July 01, 2025, when Barclays upgraded its rating to a Overweight but kept the price target unchanged to $57 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on April 07, 2025, and set its price target to $45. On March 31, 2025, Redburn Atlantic initiated with a Neutral rating and assigned a price target of $39 on the stock. BMO Capital Markets downgraded its rating to a Market Perform and decreased its price target to $60 on August 02, 2024. Leerink Partners upgraded its rating to a Outperform and raised its price target to $62 on July 24, 2024. In a note dated June 14, 2024, Bernstein upgraded an Mkt Perform rating on this stock but restated the target price of $44.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $23.95 and $51.62. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $43.37 at the most recent close of the market. An investor can expect a potential return of 19.16% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 944.43M for trailing twelve months, which represents an 100.67% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.45 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.33 points at the first support level, and at 41.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.04, and for the 2nd resistance point, it is at 46.70.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 2.87. As well, the Quick Ratio is 9.62, while the Cash Ratio is 7.63. Considering the valuation of this stock, the price to sales ratio is 7.31, the price to book ratio is 14.50.
Transactions by insiders
Recent insider trading involved Monia Brett P, Officer, that happened on Jul 30 ’25 when 2432.0 shares were purchased. Chief Executive Officer, Monia Brett P completed a deal on Jul 11 ’25 to sell 1160.0 shares. Meanwhile, Director Hayden Michael R bought 15000.0 shares on May 01 ’25.
